Three Peptides in the Delivery Room, and the Debate Behind Each One
Oxytocin is one of the most-used drugs in obstetrics. We still argue about the dose, its longer-acting cousin, and a peptide that Europe trusts and the FDA rejected.
Peptides in Women’s Health · Part 2 of 7
The proven end of the spectrum: the peptides that run labor and delivery, and the open questions behind each one.
Oxytocin is one of the oldest and most-used drugs in obstetrics. It starts labor, it strengthens labor, and it stops the bleeding that still kills mothers. It is also classed as a high-alert medication, a category for drugs that can cause serious harm when the dose runs ahead of the evidence.
The delivery room runs on peptides. Three matter most. Oxytocin, the workhorse. Carbetocin, a longer-acting version built for places where refrigeration fails. And atosiban, a peptide that does the opposite job, relaxing the uterus to hold off preterm labor. All three are real drugs with real trials. That does not mean the questions are settled.
Here is the part patients are rarely told. After more than 50 years of using oxytocin, obstetrics still does not agree on the dose. The longer-acting option works about as well as the original and is not a magic upgrade. And the uterus-relaxing peptide that is standard across Europe was turned down by the FDA. These are not fringe debates. They shape what happens to a laboring woman and her baby.
Paid subscribers continue below.
